Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
Deciphera Pharmaceuticals, Inc. (DCPH)
Today's Latest Price: $58.16 USD
1.56 (-2.61%)
Updated Jul 1 6:55pm
Add DCPH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
DCPH Stock Summary
- Deciphera Pharmaceuticals Inc's stock had its IPO on September 28, 2017, making it an older stock than merely 8.9% of US equities in our set.
- DCPH's price/sales ratio is 133.11; that's higher than the P/S ratio of 97.82% of US stocks.
- With a year-over-year growth in debt of 780.78%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses 97.7% of about US stocks.
- Stocks that are quantitatively similar to DCPH, based on their financial statements, market capitalization, and price volatility, are BBIO, EIDX, RCUS, SGMO, and EPZM.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Daily Price Range
DCPH 52-Week Price Range
DCPH Stock Price Chart Technical Analysis Charts
DCPH Price/Volume Stats
| Current price | $58.16 | 52-week high | $71.11 |
| Prev. close | $59.72 | 52-week low | $19.88 |
| Day low | $57.57 | Volume | 521,200 |
| Day high | $60.73 | Avg. volume | 587,426 |
| 50-day MA | $56.43 | Dividend yield | N/A |
| 200-day MA | $51.31 | Market Cap | 3.25B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Loading social stream, please wait...